Company Overview

Syschem (India) Limited (CIN: L24219HR1993PLC032195) is a pharmaceutical company engaged in manufacturing Active Pharmaceutical Ingredients (APIs) and bulk drugs. The company's registered office is at Village Bargodam, Tehsil Kalka, Distt. Panchkula, Haryana - 133302.

AGM Schedule and Logistics

The 33rd Annual General Meeting will be held on Wednesday, 30th September 2026 at 3:30 PM through Video Conferencing/OAVM. The deemed venue is Village Bargodam, Tehsil Kalka, Distt. Panchkula, Haryana.

Key Dates:

  • Cut-off date for voting: Wednesday, 23rd September 2026
  • E-voting commencement: Sunday, 27th September 2026 (9:00 AM)
  • E-voting ends: Tuesday, 29th September 2026 (5:00 PM)
  • AGM date: Wednesday, 30th September 2026 (3:30 PM)

The share transfer books will be closed from 24th September 2026 to 30th September 2026 (both days inclusive).

Board of Directors

  • Mr. Suninder Veer Singh (DIN: 07693557)
  • Ms. Arshdeep Kaur (Independent Director)
  • Mr. Ranjan Jain (DIN: 00635274, Managing Director)
  • Mr. Madan Lal Aggarwal (Independent Director)
  • Mrs. Renu Rawat (Independent Director)
  • Mr. Sunil Kumar Bhasin (Non-Executive Director)

Key Managerial Personnel

  • Mr. Ranjan Jain - Managing Director
  • Mr. Suninder Veer Singh - Whole Time Director
  • Ms. Shikha Kataria - Company Secretary
  • Mr. Sanjeev Agrawal - Chief Financial Officer

Auditor Changes

Statutory Auditors:

  • M/s STAV & Co (Firm Reg. No. 024510C) served till 31st August 2026
  • M/s Bansal Vijay & Associates (Firm Reg. No. 014930N) appointed from 1st September 2026 to fill casual vacancy
  • Seeking shareholder approval for 5-year term from 33rd AGM to 38th AGM

Cost Auditor: M/s Mohit Aggarwal & Co (FY 2025-26), M/s CL Bansal & Associates proposed for FY 2026-27 at remuneration of ₹75,000

Business Items for AGM Approval

Ordinary Business

1. Adoption of Financial Statements: Audited financial statements for FY ended 31st March 2026 with Board and Auditor reports

2. Director Reappointment: Mr. Ranjan Jain (DIN: 00635274) retires by rotation and seeks reappointment

3. Auditor Appointment: Approval for M/s Bansal Vijay & Associates as statutory auditors

Special Business

4. Related Party Transactions - Pharmacare International: Approval for transactions up to ₹600 crore for one year (33rd AGM to 34th AGM)

5. Related Party Transactions - Indosol Export: Approval for transactions up to ₹100 crore for one year

6. Related Party Transactions - JB Khokhani & Co: Approval for transactions up to ₹100 crore for one year

7. Cost Auditor Remuneration: Ratification of ₹75,000 for M/s CL Bansal & Associates for FY 2026-27

8. Corporate Guarantee Ratification: Continuation of ₹50 crore corporate guarantee for Pharmacare International's credit facilities

9. Director Redesignation - Ranjan Jain: Re-designation from Managing Director to Whole Time Director for 5 years with remuneration up to ₹7 lakh/month for 3 years

10. Director Redesignation - Suninder Veer Singh: Re-designation from Whole Time Director to Managing Director for 5 years with remuneration up to ₹7 lakh/month for 3 years

Financial Performance Highlights (FY 2025-26)

Income Statement:

  • Gross Income from Operations: ₹654.62 crore (Previous year: ₹386.23 crore)
  • Total Expenses: ₹639.86 crore (Previous year: ₹385.26 crore)
  • Profit Before Tax: ₹14.79 crore (Previous year: ₹1.01 crore)
  • Tax Expense: ₹3.86 crore (Previous year: ₹0.55 crore)
  • Net Profit After Tax: ₹10.93 crore (Previous year: ₹0.46 crore)

Key Ratios:

  • Debtors Turnover: 80.55 days (Previous: 84.61 days)
  • Inventory Turnover: 141.80 days (Previous: 80.16 days)
  • Interest Coverage Ratio: 13.28 times (Previous: 18.06 times)
  • Current Ratio: 1.34 (Previous: 1.30)
  • Operating Profit Margin: 2.60% (Previous: 0.26%)
  • Net Profit Margin: 1.67% (Previous: 0.12%)

Share Capital:

  • Authorized Capital: ₹62.00 crore (6 crore equity shares of ₹10 each + 2 crore preference shares of ₹1 each)
  • Paid-up Capital: ₹49.01 crore (4.90 crore shares) (Previous: ₹43.51 crore)
  • During FY 2025-26, allotted 55,00,000 shares through preferential issue at ₹49 per share

Related Party Transactions Disclosure

Pharmacare International:

  • FY 2025-26 Sales: ₹130.69 crore, Purchases: ₹132.09 crore
  • Security Deposit: ₹2.50 crore, Corporate Guarantee: ₹50 crore
  • Proposed limit: ₹600 crore

Indosol Export:

  • FY 2025-26 Sales: ₹29.98 crore
  • Proposed limit: ₹100 crore

JB Khokhani & Co:

  • FY 2025-26 Sales: ₹13.50 crore
  • Proposed limit: ₹100 crore

All transactions are stated to be at arm's length and in ordinary course of business.

Director Remuneration Proposals

Mr. Ranjan Jain:

  • Current remuneration: ₹36 lakh per annum
  • Proposed: Up to ₹7 lakh per month (₹84 lakh per annum) for 3 years
  • Tenure: 5 years as Whole Time Director
  • Shareholding: 26,55,000 equity shares (5.42%)

Mr. Suninder Veer Singh:

  • Current remuneration: ₹39 lakh per annum
  • Proposed: Up to ₹7 lakh per month (₹84 lakh per annum) for 3 years
  • Tenure: 5 years as Managing Director
  • Shareholding: 5,87,000 equity shares (1.20%)

Corporate Governance and Compliance

  • Company has adopted Whistle Blower Policy and Vigil Mechanism
  • Complied with SEBI LODR regulations except for minor delays in some filings
  • No fraud reported by auditors
  • No deposits accepted during the year
  • 88.11% shares in dematerialized form

Subsequent Events

  • Received listing approval from BSE on 16th April 2026 for 55,00,000 equity shares
  • Allotted 2,50,000 ESOP shares on 22nd June 2026
  • Allotted 43,52,500 equity shares through preferential issue on 7th July 2026

Shareholder Information

  • Registrar & Transfer Agent: M/s Beetal Financial & Computer Services Pvt. Ltd., New Delhi
  • E-voting through CDSL platform
  • Public notice published in Financial Express (English) and Hindi newspaper on 04.09.2026